METHODS AND KITS FOR RISK ASSESSMENT OF BARRETT'S NEOPLASTIC PROGRESSION

摘要

The present invention is based on the seminal discovery of a set of biomarker assays to predict the risk of esophageal cancer or ad vanced precancerous esophageal lesions in patients with Barrett's esophagus (BE). The present invention includes, but is not restricted to biomarkers based on gene hypermethylation (CH3), as well as biomarkers based on loss of heterozygosity (LOH), both occurring in Barrett's esophagus tissue biopsy samples. Results of the assay provide patients and their caregivers with an assessment of the likelihood of future neoplastic (irankiy cancerous or advanced precancerous) progression.